Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma

In this multicenter, single‐arm, phase II study, the efficacy and safety of ibrutinib were examined in Japanese patients with relapsed or refractory mantle cell lymphoma (MCL). Patients (age ≥20 years) with relapsed or refractory MCL who had progressed after receiving at least one prior treatment re...

Descripción completa

Detalles Bibliográficos
Autores principales: Maruyama, Dai, Nagai, Hirokazu, Fukuhara, Noriko, Kitano, Toshiyuki, Ishikawa, Takayuki, Shibayama, Hirohiko, Choi, Ilseung, Hatake, Kiyohiko, Uchida, Toshiki, Nishikori, Momoko, Kinoshita, Tomohiro, Matsuno, Yoshihiro, Nishikawa, Tomoaki, Takahara, Satoko, Tobinai, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198949/
https://www.ncbi.nlm.nih.gov/pubmed/27616553
http://dx.doi.org/10.1111/cas.13076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198949/
https://www.ncbi.nlm.nih.gov/pubmed/27616553
http://dx.doi.org/10.1111/cas.13076

Ejemplares similares